BioMarin's Second MPS Drug, Naglazyme, Approved By FDA June 2, 2005 By Jennifer Boggs BioMarin Pharmaceutical Inc. is wasting little time getting to the market with its newly approved enzyme-replacement therapy, Naglazyme, for patients with mucopolysaccharidosis VI. (BioWorld Today)Read More
